| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2579625 | Thérapie | 2007 | 6 Pages |
Abstract
A retrospective observational study was carried out in the Midi-Pyrenees area, from the point of view of health insurance, to compare the consumed health resources between two cohorts of patients, one treated by etanercept (Enbrel®) and the other by leflunomide (Arava®). Two hundred and fifty three patients were included in the etanercept cohort and 539 in the leflunomide cohort. The average annual PR cost for a patient treated with etanercept is 13 936 ⬠and 5 764 ⬠for a patient treated with leflunomide. The health costs avoided by recourse to etanercept do not compensate the high cost of this drug.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology, Toxicology and Pharmaceutics (General)
Authors
Blandine Juillard-Condat, Arnaud Constantin, Anne Cambon-Thomsen, Robert Bourrel, Florence Taboulet,